12 sourced events on published monthly calendars (dates may have resolved)Updated 2026-10-02

Know what the readout has to prove — before it prints.

ClinicalInvestor turns FDA decision dates, clinical trial designs, and company pipelines into a plain-English checklist: what the bar is, what would count as a miss, and which risks the press release will not mention.

Published under a public editorial policy and disclosures. Educational research, not investment advice.

12

Sourced events on published calendars

9

Company profiles

6

Monthly calendars published

2026-10-02

Catalyst data last updated

Counts are generated from published content at build time, not estimated. How we build this.

PDUFA calendar

Top tool

Every FDA decision date we publish links to the company filing that states it and quotes the sentence it was read from. No recalled dates, no guesses.

View the PDUFA calendar →

Trial Translator

Free tool

Paste any ClinicalTrials.gov ID and get an instant plain-English breakdown — live registry data plus a rules-based investor checklist covering endpoint, design, enrollment, and timeline. No jargon, no signup.

Translate a trial →

Free tools for the basics. Pro for the catalyst decision.

We pull from ClinicalTrials.gov, SEC EDGAR, and FDA sources, then turn it into watchlists, risk flags, and investor checklists you can actually act on.

Catalyst calendar

Phase 3 readouts and FDA decisions we can trace to a primary source — each one dated, sourced, and explained in plain English.

Trial Translator

Paste any ClinicalTrials.gov ID. Get the endpoint, the design, and the investor checklist back in plain English — from live registry data.

Company profiles

Pipelines, bull and bear cases, and cash-runway context for the clinical-stage names most likely to move on a catalyst.

Biotech screener

Filter clinical-stage companies by therapeutic area, lead pipeline phase, and market cap. Free, no signup.

Learn biotech

From "what is a PDUFA date" to reading a survival curve without pretending you already can.

Weekly briefing

Every Sunday: the catalysts landing this week, what the bar is, and what would count as a miss. Free.

Therapeutic areas we cover

Company counts below are the profiles currently published in each area. Each one opens the area's companies with their filing figures, trial milestones and FDA dates.

The parts most sites leave out.

Biotech investing punishes false confidence. So does a research site that overstates what it knows. Here is what we commit to instead.

Sources are named

Trial data comes from ClinicalTrials.gov, filings from SEC EDGAR, decision dates from FDA. Company pages link the registry record.

AI drafts are labelled

Analysis drafted with AI assistance says so, and a page claims a human review only when one happened. Corrections are dated and shown on the page they fix.

We publish the limits

Dated content shows when it was last updated. Where our coverage is thin, the page says so rather than rounding up.

Read the methodology, the editorial policy, or our disclosures.

Stay ahead of the readout

Start with the free weekly briefing. Upgrade when you want the full ranked watchlist and risk flags.

Free catalyst calendar

$0/month

  • Printable monthly catalyst calendar
  • Weekly catalyst briefing
  • Full catalyst calendar access
  • Screener and Trial Translator
  • All published guides and analysis

Free weekly biotech briefing. No spam. We only use this address for the briefing. By subscribing, you agree to our Privacy Policy and Terms.

ClinicalInvestor Pro

$29/month

or $249/year

  • Everything in Free, plus:
  • Full ranked monthly Catalyst Watchlist
  • Trial, FDA, and financing risk flags
  • Unlimited Trial Translator workflow
  • Premium catalyst memos and memo archive
  • Saved-watchlist and alert workflow roadmap

Cancel anytime. Billing handled securely through Stripe.

Read a full sample memo first →

Educational research only. No financial advice, and no recommendation to buy or sell any security. Free briefing — unsubscribe any time. Some affiliate links may earn compensation; see our disclosures.